Dabigatran makers face legal action

US lawyers are launching the first “injury and death” cases against the makers of dabigatran alleging that patients on the drug face unacceptable risk of irreversible bleeds.

Dabigatran (Pradaxa), made by Boehringer Ingelheim (BI), is currently being prescribed to around 25,000 patients in Australia with atrial fibrillation.

Legal firm Watts Guerra Craft, which filed its action in the US federal courts this week, said it wanted the anticoagulant withdrawn from the market and is now appealing for patients who believe they were